Clinical Trial

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with…

8 months ago

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase…

8 months ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing…

8 months ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable,…

8 months ago

PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53…

8 months ago

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational…

8 months ago

Spectral Medical Announces First Quarter and Provides Corporate Update

Tigris Trial Enrollment completedTopline results expected to be released in August 2025Entered into an up to US$10 million Promissory Note…

8 months ago

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (NASDAQ: CGTX), a clinical-stage company developing drugs that treat…

8 months ago

Critical Path Institute Celebrates 20 Years of Advancing Drug Development through Innovation and Collaboration

TUCSON, Ariz., May 8, 2025 /PRNewswire/ -- The year 2025 marks a historic milestone for Critical Path Institute® (C-Path), as the…

8 months ago

Amavita Heart and Vascular Health Achieves Two Prestigious IAOCR Certifications

MIAMI, May 8, 2025 /PRNewswire/ -- Amavita Heart and Vascular Research Services LLC the research arm of Amavita Heart and…

8 months ago